AstraZeneca presents new data to support patients living with cardiovascular, renal and metabolic (CVRM) diseases at three international congresses this spring

57th European Renal Association - European Dialysis and Transplant Association Virtual Congress, Heart Failure Association Discoveries and the 80th American Diabetes Association Virtual Scientific Sessions


At AstraZeneca, we are committed to advancing science and bringing life-changing therapies to those who need them most. The COVID-19 pandemic has required us to be flexible and adapt how we work in the current climate, and we are determined to share our practice-changing science in new virtual formats alongside healthcare professionals.

We are evolving with our congress partners and presenting more than 50 abstracts across three cardiovascular, renal and metabolic focused congresses this June. These abstracts will share new insights from Farxiga (dapagliflozin), roxadustat, Lokelma (sodium zirconium cyclosilicate) and Brilinta (ticagrelor) across heart failure (HF), type-2 diabetes (T2D), chronic kidney disease (CKD) and cardiovascular (CV) disease. 

Data will showcase our innovative approach to addressing unmet needs in CVRM from early prevention, protection and treatment, to slowing progression and managing serious complications, and reinforces our ambition to protect the lives of 50 million people in 2020 from the often-devastating consequences of cardiovascular, renal and metabolic diseases.
 


The pharmaceutical industry has evolved instinctively in reaction to COVID-19. It is important that we continue to collect and discuss industry innovation, and the virtual congress format has enabled even wider sharing amongst the industry. We look forward to presenting our data and insights which we hope will continue to improve the standard of care for patients.

Joris Silon Senior Vice President, Global Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals Business Unit

Here’s an overview of what AstraZeneca is presenting:



At the 57th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress, 6 to 9 June 2020, we will present 20 abstracts, including four oral presentations, highlighting data on Lokelma (sodium zirconium cyclosilicate), roxadustat and Farxiga (dapagliflozin) covering various stages of CKD and demonstrating our ongoing commitment to exploring treatment options across the full continuum of renal care.



From 5 to 19 June 2020 we will participate in Heart Failure Association Discoveries, a virtual format replacing ESC-HF which was cancelled earlier this year in light of COVID-19. Our data will further explore the landmark DAPA-HF trial investigating Farxiga in adult patients with heart failure with reduced ejection fraction.



We will also share 25 abstracts at the 80th American Diabetes Association Virtual Scientific Sessions, taking place 12 to 16 June 2020. These abstracts will showcase the depth and breadth of potential cardio, renal and metabolic benefits for patients across our portfolio.




Type-2 diabetes is associated with multiple risk factors and comorbidities.[8] Navigating one or more cardiovascular, renal or metabolic disease is a complicated journey for patients. As we reflect on the current environment, we are also working hard to push the boundaries of science so that we can better support patients. Our trials and real-world evidence presented this June show how we can evolve our therapies to truly reflect patients’ changing needs throughout their journey. We look forward to virtually connecting with experts across the globe on how we are developing and growing therapies that address multiple risk factors across cardiovascular, renal and metabolic disease.”

Elisabeth Björk SVP, Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D

Globally, heart failure affects approximately 64 million people – with the elderly population affected disproportionally.[2,9,10] As the aging population increases, it will be even more important to uncover emerging science and potential solutions to ease the burden of this vulnerable population. Our focus now is to really understand different subpopulations of patients, so we can develop the right treatment for the right patient category.

Regina Fritsche-Danielson SVP, Research and Early Development,Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D

Chronic kidney disease can be a heavy burden on patients.[7] On one hand, it is not diagnosed until it’s advanced and on the other, there is no known cure but to slow its progression.[11] Data presented this June reinforces our ambition to create a seamless pathway enabling better management of chronic kidney disease and it’s complications, potentially improving outcomes and lowering mortality rates. This is a particularly important time for our renal portfolio, as we present data which seeks to accelerate potential solutions to treat life-threatening complications and slow CKD progression.

Marie-José (MJ) Hoellinger Global Product Leader & VP Commercial, Lokelma & Bydureon


Learn more about our work in CVRM:

Our aim is to protect the lives of 50 million people in 2020 from the often-devastating consequences of heart failure, cardiovascular, metabolic, and renal diseases. Learn more about how we are:
 


Follow us on social to join the conversation around #ERAEDTA20#HFAdiscoveries and #ADA2020


References:

1. World Health Organization. WHO World Heart Day: Scale up prevention of heart attack and stroke: World Health Organization; 2019 [cited 2019 Feb 19]. Available from: URL: https://www.who.int/cardiovascular_diseases/world-heart-day/en/.

2. Vos T et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390(10100):1211–59.

3. National Health Service. Symptoms: Chronic kidney disease; 2016 [cited 20.08.19]. Available from: URL: https://www.nhs.uk/conditions/kidney-disease/symptoms/.  

4. International Diabetes Federation. IDF Diabetes Atlas - 9th Edition. 9th ed.; 2019 [cited 2020 June 10]. Available from: URL: https://www.diabetesatlas.org/.

5. Hayes A et al. Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study. Value Health 2016; 19(1):36–41.

6. Bikbov B et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2020; 395(10225):709–33.)

7. Centers for Disease Control and Prevention (CDC). Chronic Kidney Disease in the United States, 2019; 2019/03/11 [cited 2020 June 09]. Available from: URL: https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html.

8. Arnold SV et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab 2018; 20(8):2000–3.

9. Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol 2014; 11(4):329–37.

10. World Health Organization. Ageing and health; 2018 [cited 2020 June 3]. Available from: URL: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health.

11. National Institute of Diabetes and Digestive and Kidney Diseases. Slow Progression & Reduce Complications [cited 2020 Mar 06]. Available from: URL: https://www.niddk.nih.gov/health-information/professionals/clinical-tools-patient-management/kidney-disease/identify-manage-patients/manage-ckd/slow-progression-reduce-complications.  

 


Abstract List

57th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress

ERA-EDTA 2020

The ERA-EDTA 2020 abstract book is published here and will be archived in this location: https://www.era-edta.org/VirtualCongress2020/Accepted_Abstracts_ERAEDTA_2020.pdf.
 

Lokelma (sodium zirconium cyclosilicate)

  • Healthy K-rich Diet in Chronic Kidney Disease (CKD) Patients Using Sodium Zirconium Cyclosilicate (SZC) to Control Hyperkalemia: A Feasibility Study (HELPFUL) - Avesani, C.M. (Poster presentation, abstract #P0941)
  • Effectiveness of Sodium Zirconium Cyclosilicate (SZC) in Haemodialysis Patients with Severe Hyperkalaemia in the DIALIZE Study - Ford, M. (Poster presentation, abstract #P0220)
  • The Association Between HK Risk and Cardiovascular and Renal Comorbidities in a Large Real-World Cohort of CKD Patients – Hoskin, L. (Poster presentation, abstract #P0671)
  • Subgroup Efficacy Analysis of Sodium Zirconium Cyclosilicate (SZC) in Hyperkalaemic Haemodialysis Patients in the DIALIZE Study - McCafferty, K. (Poster presentation, abstract #P0242)
  • Sodium Zirconium Cyclosilicate Corrects Hyperkalaemia within 72 hours Among Outpatients with Severe Hyperkalaemia (Baseline Serum Potassium ≥6 mmol/L) Regardless of Renal Function Level or RAASi Use: Post Hoc Subgroup Analysis of a Phase 3 Trial - Packham, D. (Poster presentation, abstract #P0189)
  • A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of the Effects of 12 Weeks of Sodium Zirconium Cyclosilicate (ZS-9) on Albuminuria (UACR) in Patients with Type 2 Diabetes and Hyperkalemia - Persson, F. (Poster presentation, abstract #P1017)
  • KEEP ON (KEEping RAAS inhibition treatment with optimal Potassium cONtrol). Design of a Clinical Trial of Using Sodium Zirconium Cyclosilicate for Keeping RAAS Inhibition and/or MRAs in Patients with Chronic Kidney Disease and Congestive Heart Failure History - Puchades, M.J. (Poster presentation, abstract #P0200)
  • Sodium Zirconium Cyclosilicate Increases Serum Bicarbonate Concentrations Among Patients with Hyperkalaemia: Results from Three Randomized, Multi-Dose, Placebo-Controlled Trials - Roger, S.D. (Poster presentation, abstract #P0198)
  • Patterns of Hyperkalaemia Recurrence Among Chronic Kidney Disease Patients in UK Clinical Practice – Hurst, M. (Poster presentation, abstract #P0683)

Roxadustat

  • A Qualitative Study of Patients’ Preference for the Treatment of Anaemia Associated With Chronic Kidney Disease - Alexandre, A.F. (Electronic poster presentation, abstract #P0865)
  • PRE-ESKD Haemoglobin Target Attainment and Post-Dialysis Outcomes in Patients with Renal Anaemia: A Nationwide Study - Xu, Y. (Poster presentation, abstract #P1372)
  • Roxadustat for the Treatment of Anaemia in Chronic Kidney Disease Patients Not on Dialysis: A Phase 3, Randomised, Open-Label, Active-Controlled Study - Barratt, J.  (Webcast, abstract #MO001, Monday, 08 June, 08:54 –09:04 CEST, Silver Plenary)
  • Effect of Severe Renal Impairment or End-Stage Renal Disease on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor - Groenendaal-van de Meent, D. (Webcast, abstract #SO052, Sunday, 07 June, 15:57 –16:07 CEST, Red 1-2)
  • A Real World Longitudinal Analysis of Anemia Treatment Prescriptions in Non-Dialysis-Dependent Chronic Kidney Disease Patients, a CKDopps Study - Lopes M.B (Webcast, abstract #SO053, Sunday, 07 June, 16:10 –16:20 CEST, Red 1-2)
  • Ophthalmological Effects of Roxadustat in the Treatment of Anaemia in Chronic Kidney Disease Patients on Dialysis: Sub-Analysis of a Phase 3, Randomised, Double-Blind, Active-Comparator Conversion Study - Sepah, Y (Webcast, abstract #MO002, Monday, 08 June, 09:07–09:17 CEST, Silver Plenary)
  • Farxiga (dapagliflozin)
  • Clinical Characteristics and eGFR and UACR Distribution According to the 2012 KDIGO CKD Classification: A Report from the US DISCOVER CKD Cohort - Garcia Sanchez, J.J. (Poster presentation, abstract #P0816)
  • Characterization of a DAPA-CKD-like Population Using a Contemporary US Healthcare System: Cohort Characteristics and Clinical Outcomes - Olufade, T. (Poster presentation, abstract #P0696)
  • Healthcare Resource Utilization and Costs in a DAPA-CKD-like Population Using a Contemporary US Healthcare Cohort - Olufade, T. (Electronic poster presentation, abstract #P0788)
  • Estimating the Burden of Chronic Kidney Disease (CKD) in the UK: Comparison of Two Health Economic Policy Analysis Methods - Xu, M. (Poster presentation, abstract #P0773)

CVRM (Chronic Kidney Disease)

  • Complement Factor Bb and Factor C4d in IgA Nephritis and IgA Vasculitis - Westergren, E. (Electronic poster presentation, abstract #P0347)

Heart Failure Association Discoveries

HFA Discoveries

FREE access to all ESC 365 content until July 31, 2020; From August 1, 2020 onwards, only members can view the abstracts.
 

Farxiga (dapagliflozin)

  • Prevalence of Main Comorbidities Among Patients with Heart Failure: A Systematic Review – Hunt P. (ePoster, Monday, 15 June)
  • Translating Findings from the Landmark DAPA-HF Study: A Multinational Cost-effectiveness Analysis of Dapagliflozin in the Treatment of Heart Failure with Reduced Ejection Fraction – McMurray, J. (PowerPoint presentation, Monday, 15 June)
  • Effect of Dapagliflozin on Outcomes in Women and Men with Heart Failure with Reduced Ejection Fraction in the DAPA-HF Trial – Butt J. (PowerPoint presentation, Monday, 15 June)
  • Effect of Dapagliflozin on Outcomes According to Aetiology in Patients with Heart Failure and Reduced Ejection Fraction in the DAPA-HF Trial – Butt J. (PowerPoint presentation, Monday, 15 June)
  • Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF – McMurray, J. (Oral presentation, Friday, 5 June, 17:15-17:30 CEST)
  • Effect of Dapagliflozin on Outpatient Worsening in Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF – McMurray, J. (Oral presentation, Friday, 19 June, 17:30-17:45 CEST)

CVRM (Heart Disease)

  • Heart Failure Prevalence, Patient Characteristics and Outcomes: A Large Observational Study – Banerjee A. (v.o. PowerPoint presentation, Monday, 15 June)
  • Heart Failure and Health Care Costs: A Full-Population Observational Study – Norhammer A. (ePoster PDF, Monday, 15 June)
  • Sex Differences in Biomarkers Associated with Coronary Microvascular Disease Among Patients with Heart Failure with Preserved Ejection Fraction – Chandramouli C. (ePoster PDF, Monday, 15 June)
  • Healthcare Resource Utilisation and Health Outcomes Among Young Patients with Heart Failure: A Contemporary Real-world US Study – Vaduganathan M. (ePoster PDF, Monday, 15 June)

Lokelma (sodium zirconium cyclosilicate)

  • The Effect of the Frequency and Severity of Hyperkalaemia on Health Outcomes in Heart Failure Patients – McEwan P. (ePoster, Monday, 15 June)
  • The Relationship Between Cardiovascular and Renal Comorbidities and Hyperkalaemia in a Large Real-world Cohort of UK Heart Failure Patients – McEwan P. (ePoster, Monday, 15 June)
  • Patterns of Hyperkalaemia Recurrence Among Heart Failure Patients in UK Clinical Practice – McEwan P. (ePoster, Monday, 15 June)
  • Sodium Zirconium Cyclosilicate to Enable Renin-Angiotensin-Aldosterone-System Inhibitor Maximisation in Heart Failure Patients with CKD: Design of the LIFT Study, a Randomised Double-Blind, Placebo Controlled Trial – Banerjee D. (ePoster, Monday, 15 June)

 

80th American Diabetes Association Virtual Scientific Sessions

ADA 2020

Only abstract titles are available at this time. Embargoed text of abstracts will be made available online on Tuesday, June 9, 2020. ADA ePosters are archived and available on their website.

Cotadutide (MEDIO382)

  • Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content - Robertson, D. (Oral Presentation #354-OR, Monday, 15 June, 17:30 –17:45 CT)
  • Cotadutide (medi0382), A Dual Receptor Agonist with Glucagon-like Peptide-1 And Glucagon Activity, Is Well-tolerated (<600 μG) With Robust Effects on Blood Glucose In Patients With T2dDM - Robertson, D. (Poster Presentation #951-P, Saturday, 13 June, 10:00 –11:00 CT)
  • Cotadutide, a GLP-1/Gcg Receptor Co-agonist Improves Insulin Sensitivity and Restores Normal Insulin Secretory Capacity in DIO Mice - Laker, R.C. (Poster Presentation #1800-P, Saturday, 13 June, 10:00–11:00 CT)
  • A Direct AMPK Activator Reduces Liver Steatosis in a Mouse Model of NASH - Mather, K. (Poster Presentation #1820-P, Saturday, 13 June, 10:00–11:00 CT)

Farxiga (Dapagliflozin)

  • Effect of Dapagliflozin On the Incidence of Diabetes: A Prespecified Exploratory Analysis From DAPA-HF - Inzucchi, S.E. (Oral Presentation #271-OR, Monday, 15 June, 8:00 –8:15 CT)
  • Effect of Dapagliflozin on Risk for Fast Decline in eGFR: Analyses from the DECLARE-TIMI 58 Trial - Raz, I. (Oral Presentation #303-OR, Monday, 15 June, 14:30–14:45 CT)
  • Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents Analyses from DECLARE-TIMI 58 - Cahn, A. (Poster Presentation #1101-P, Saturday, 13 June, 10:00–11:00 CT)
  • Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients with Type 2 Diabetes - Ang, L. (Poster Presentation #554-P, Saturday, 13 June, 10:00 –11:00 CT)
  • Effects of Long-term Dapagliflozin Treatment on Hemorheology (D-PATH Study) - Ono, S. (Poster Presentation #1106-P, Saturday, 13 June, 10:00 –11:00 CT)
  • Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF trial - Docherty, K.F. (Poster Presentation #1112-P, Saturday, 13 June, 10:00 –11:00 CT)
  • Dapagliflozin Suppresses Adipose Fatty Acid Accumulation in Rats Fed on High-Fat Diet but not on Normal Chow - Sato, D. (Poster Presentation #1946-P, Saturday, 13 June, 10:00 –11:00 CT)
  • Changes in Plasma Levels of Liver Enzymes in Response to Dapagliflozin, Metformin or Exercise in People with Prediabetes: The PRE-D Trial - Faerch, K. (Poster Presentation #845-P, Saturday, 13 June, 10:00 –11:00 CT)
  • Effects of Dapagliflozin, Metformin or Exercise on Plasma Glucagon Concentrations in Individuals with Prediabetes: The PRE-D Trial - Clemmensen, K.K.B. (Poster Presentation #844-P Saturday, 13 June 10:00 –11:00 CT)
  • Dapagliflozin Promotes Adipose Beiging and Lipolysis and Reduces Adipocyte Size in the Obese Prediabetic Dog - Kabir, M. (Poster Presentation #1711-P, Saturday, 13 June, 10:00 –11:00 CT)

DISCOVER

  • HbA1c < 7.0% 6 Months after Initiation of Second-Line Therapy in Patients with Uncontrolled Type 2 Diabetes is Associated with Good Glycemic Control at 3 Years: The DISCOVER Study - Bonnet, F. (Poster Presentation #1598-P, Saturday, 13 June, 10:00 –11:00 CT)
  • Quality of life in people with type 2 diabetes following initiation of second-line therapy: DISCOVER - Nicolucci, A. (Oral Presentation #40-OR, Friday, 12 June, 18:00–18:15 CT)
  • Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study - Khunti, K. (Poster Presentation #1590-P, Saturday, 13 June, 10:00 –11:00 CT)

Bydureon (Exenatide)

  • Once-weekly Exenatide Effects on eGFR Slope and UACR as a Function of Baseline UACR: An EXSCEL Trial Post Hoc Analysis - Clegg, L.E. (Poster Presentation #958-P, Saturday, 13 June, 10:00 –11:00 CT)

Brilinta (ticagrelor)

  • Impact of Diabetes-Related Factors And Background Antihyperglycemic Therapy On The Efficacy And Safety Of Ticagrelor Added To Aspirin: Insights From The THEMIS Trial - Leiter, L.A. (Poster Presentation #403-P, Saturday, 13 June, 10:00 –11:00 CT)

Early Research & Development

  • A Direct AMPK Activator Reduces Liver Steatosis in a Mouse Model of NASH - Mather, K. (Poster Presentation #1820-P, Saturday, 13 June 10:00 –11:00 CT)
  • Synergetic and Distinct Roles in the Control of Food Intake and Energy Balance for Subpopulations of NTS Neurons - Cheng, W. (Late-Breaking Poster Presentation #196-LB, Saturday, 13 June, 10:00 –11:00 CT)
  • Discrepancy between Single-Cell RNA Sequencing and Protein Expression Assessments of GLP-1Rr Heterogeneity in Beta Cells - Gray, S.M. (Poster Presentation #2113-P, Saturday, 13 June, 10:00 –11:00 CT)
  • Quantification of GLP-1R Trafficking in Primary Beta Cells in Response to Different Ligands - Gray, S.M. (Poster Presentation #2114-P, Saturday, 13 June 10:00 –11:00 CT)

Veeva ID: Z4-24962
Date of Preparation: June 2020
Date of Expiry: June 2022